Transforming the understanding and treatment of neurodegeneration and aging

Eti Yoles, Ph.D.

Chief Operating Officer

●●

More than 20 years of high-level experience in managing biotechnology research and development, specifically in the field of neuro-immunology. Prior to joining ImmunoBrain Checkpoint, Eti served as CSO of Immunobrain Therapies, and prior to that, as managing director of NeuroQuest and as VP of Product R&D at Proneuron Biotechnologies. Dr. Yoles holds a B.Sc. in biology, M.Sc. in physiology, and Ph.D. in neurobiology from Bar Ilan University.

Jesse M. Cedarbaum, MD

Chief Medical Officer

●●

Served as Vice President, Movement and Neuromuscular Disorders Clinical Development at Biogen Idec between 2014-2019. Prior to joining Biogen, Dr. Cedarbaum was Vice President, Global Clinical Development for Neuroscience at Bristol-Myers Squibb, where he was responsible for late-stage programs in neurology and psychiatry. He has also held senior clinical development positions at Cytokinetics, Elan and Regeneron.

Mr. Nathan Hevrony

Co-founder and Executive Chairman

●●

Investor with a large portfolio of holdings with 35 years of experience in private equity and merchant banking, and 22 years of experience financing and developing life science technologies. Chairman of the Board and the controlling shareholder of Babcock Power. Board member and investor in various private companies. Philanthropist.

Carol David, Ph.D.

VP Manufacturing and Product Development

●●

Over 20 years of pharmaceutical industry experience. She has worked for both diagnostic and biopharmaceutical companies, following products from early development through regulatory submission. Most recently, Carol was head of the Biosimilar CMC group at Teva Pharmaceuticals, leading a multi-functional team for development of several biosimilar products. Carol holds an M.Sc. and Ph.D. in Immunology from the WIS, and has post-doctoral experience at Yale University.

Kuti Baruch, Ph.D.

Head of Research and Development

●●

Over 10 years of biomedical research experience in the fields of neuroimmunology and therapeutic approaches to neurodegenerative conditions. During his Ph.D. studies at Prof. Schwartz’s laboratory, his research focused on brain-immune system crosstalk in neurodegenerative diseases, and targeting the peripheral immune system as a novel therapeutic approach for Alzheimer’s disease. Kuti holds a M.Sc. in Medical Science from Tel-Aviv University, and a Ph.D. in Neurobiology from the Weizmann Institute of Science.

Dalia Bracha (RN, BSN, MPA)

Head of Clinical Management and Operations

●●

An experienced clinical Project Manager with more than 20 years of demonstrated management of global clinical studies (phase I-IV) across the US, EU and Israel, having worked across large global pharmaceuticals and emerging biotech companies.

Ronit Epstein-Monin, M. Pharm, MPH

Head of Regulatory Affairs

●●

Regulatory affairs professional with over 20 years of hands-on experience in the development of innovative medicinal products. She has in-depth understanding of regulatory requirements for the development of drug-device combination products, drugs and biologics from early phase development through to phase 3 trials and subsequent NDA and MA. Ronit has worked in large biotech companies with wealth of experience in communications with the FDA and the EMA.